PIVOT-12 : a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence - Eggermont, Alexander (Princess Máxima Center for Pediatric Oncology & University Medical Center Utrecht) ; Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G Pascale) ; Khushalani, Nikhil I. (H Lee Moffitt Cancer Center & Research Institute) ; Schadendorf, Dirk (West German Cancer Center at the University Hospital Essen) ; Boland, Genevieve (Massachusetts General Hospital (Boston)) ; Weber, Jeffrey (Perlmutter Cancer Center at NYU Langone Health) ; Lewis, Karl D. (University of Colorado Cancer Center) ; Johnson, Daniel (Ochsner Medical Center) ; Rivalland, Gareth (University of Auckland & Auckland City Hospital) ; Khattak, Adnan (Hollywood Private Hospital. Edith Cowan University) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Gogas, Helen (National & Kapodistrian University of Athens) ; Long, Georgina V. (Melanoma Institute Australia. University of Sydney. Royal North Shore & Mater Hospitals) ; Currie, Sue L. (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Chien, David (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Tagliaferri, Mary A. (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Carlino, Matteo S. (Westmead & Blacktown Hospitals & Melanoma Institute Australia. University of Sydney) ; Diab, Adi (University of Texas MD Anderson Cancer Center)